Efficacy and safety of early pancreatic duct stenting for unresectable pancreatic cancer: A randomized controlled trial

Table 6 Comparison of nutritional status between the two groups

	Double-stent group (n = 40)	Single-stent group (n = 38)	P value
Albumin, mean ± SD, g/L
Preoperative	33.5 ± 5.4	33.7 ± 4.9	0.866
After 3 months	35.1 ± 4.2	35.0 ± 4.7	0.962
After 6 months	35.2 ± 4.6	32.2 ± 4.1	0.179
Serum total protein, mean ± SD, g/L
Preoperative	63.5 ± 6.8	62.2 ± 7.4	0.431
After 3 months	63.4 ± 7.1	62.6 ± 5.9	0.775
After 6 months	66.6 ± 8.4	60.4 ± 4.0	0.046
BMI, mean ± SD, kg/m2
Preoperative	21.3 ± 3.1	20.8 ± 3.1	0.448
After 3 months	19.7 ± 2.9	19.4 ± 3.2	0.756
After 6 months	20.3 ± 3.1	17.9 ± 2.7c	0.061

^cP < 0.001, at 6 months after endoscopic retrograde cholangiopancreatography, only the decrease of body mass index in the single-stent group was statistically significant.

The double-stent group underwent endoscopic retrograde cholangiopancreatography with a fully-covered self-expandable metallic biliary stent and a pancreatic duct stent, while the single-stent group underwent a fully-covered self-expandable metallic biliary stent only. BMI: Body mass index.